TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05401175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion with haematopoietic stem cells
Description: Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemoradiotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemoradiotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
Study: NCT05766241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Strategies Training
Description: In SST, participants will be introduced to the concept of sensory processing in the context of PTSD and will learn about the ways in which difficulties in this area can impact their affective, cognitive, and functional outcomes. Participants will learn about the effects of PTSD symptoms on their ability to regulate stressful situations and engage in social interactions, as well as the benefits of physical activity and proper sleep hygiene. Participants will also identify functional goals (e.g., reduce sensation-avoiding, better regulate physical and emotional reactions to trauma reminders, increase sensory sensitivity, etc.) which they will aim to achieve with the knowledge and resources gained from SST. Throughout the program, participants will learn various strategies to help with movement, sleep, and interacting with others, and will have opportunities to practice the strategies identified as being relevant to their specific needs during their baseline sensory assessment.
Study: NCT06213259

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, SQ
Study: NCT05983380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Mobility and Grip Strengthening Exercises
Description: Addition of hand mobility and grip strengthening exercises to the usual care for breast cancer-related lymphedema to assess changes in limb volume, quality of life, and hand function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Manual lymphatic drainage, compression, exercise, skin hygiene.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Manual lymphatic drainage, compression, exercise, skin hygiene.
Study: NCT04746053

Intervention type: OTHER
Group type: OTHER
Intervention: Pelvic ultrasound
Description: Pelvic or vaginal ultrasound

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: blood sample (5ml)
Study: NCT00561366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo t.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: capsule, 400 mg t.i.d.
Study: NCT06034418

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse radiofrequency treatment
Description: In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, pulse radiofrequency will be applied to each nerve in 2 cycles of 120 seconds for the patients in this group. The pulse radiofrequency current will be 20 milliseconds wide and 45 volts in size. The tip temperature shall not be more than 42℃.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block with 1 cc betamethasone and 1 cc 1% lidocaine
Description: In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, patients will be injected with 1 cc betamethasone and 1 cc 1% lidocaine for each nerve. A total of 2 cc volume will be injected for each nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block with 1 cc betamethasone and 1 cc 1% lidocaine
Description: In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, patients will be injected with 1 cc betamethasone and 1 cc 1% lidocaine for each nerve. A total of 2 cc volume will be injected for each nerve.
Study: NCT05074927

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: diaphragm ultrasonography
Description: For all patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) : diaphragm ultrasonography at 3 (M0) and 6 months (M3) after the end of his hospitalisation
Study: NCT05170438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill,Paclitaxel
Description: Regimen Every 28 days as one cycle.Lenvatinib 16 or 12 mg/day orally (depends on the result of safety run-in phase), on day 1-28; Paclitaxel 80 mg/m2 in 250-500 mL of normal saline, intravenously over 2 hours on day 1, 8, 15.
Study: NCT04693403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: 40-60l/min humidified oxygen by nasal cannula

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Oxygen therapy by boussignac Continuous positive airway pressure face mask

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oxygen
Description: Oxygen therapy by low flow (upto 15l/min) by Non-rebreather face mask
Study: NCT05375916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Sustained-release hydromorphone is a long-acting preparation opioid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Sustained-release hydromorphone is a long-acting preparation opioid
Study: NCT05440032

Intervention type: DIAGNOSTIC_TEST
Intervention: Semi-quantitative electrochemical leukocyte esterse test strip
Description: Electrochemical assay to detect level of leukocyte esterase in sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Roche Chemstrip
Description: Urinalysis chemstrip
Study: NCT05224830

Intervention type: OTHER
Intervention: Nijmegen questionnaire score
Description: We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome

Intervention type: OTHER
Intervention: Nijmegen questionnaire score
Description: We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome
Study: NCT03185000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR004 (Treg immunotherapy)
Description: Administered Intravenously (IV)
Study: NCT06045117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPumlonary Management System (CPM)
Description: The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
Study: NCT05999643

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Drug: 68Ga-FAPI
Description: Intravenous injection of one dosage of 111-185 MBq (3-5 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image SpA lesions in SI joints, spine, musculoskeletal and the extra-articular involvement by PET/CT.
Study: NCT06222268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) only
Description: Cannabis consisting of 2.5mg CBD and 0mg Delta-9-tetrahydrocannabinol (THC) is delivered through a vaporizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo only
Description: Placebo is administered in the same way as active drugs through the vaporizer. Placebo cannabis material obtained through National Institute of Drug Abuse (NIDA) contains 0mg THC and 0mg CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (THC) only
Description: Cannabis containing 2.5mg THC and 0mg CBD is delivered through a vaporizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC:CBD 1:1
Description: Cannabis containing 2.5mg of THC and 2.5mg of CBD is delivered through a vaporizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC:CBD 1:10
Description: Cannabis containing 2.5mg THC and 25mg CBD is delivered through a vaporizer.
Study: NCT06194916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: A 4-WEEK SELF-MANAGEMENT TRAINING WILL BE PROVIDED THROUGH THE WEB-BASED TRAINING SITE.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL GROUP
Description: THEY WILL RECEIVE THE ROUTINE CARE GIVEN TO PATIENTS WITH EPILEPSY.
Study: NCT06120725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT05805436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: Patients in the intervention arm will take polyethylene glycol 3350 for three days before robotic urologic surgery. Patients in the control arm will not.
Study: NCT06274372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flow controlled ventilation
Description: effects of flow controlled ventilation

Intervention type: DEVICE
Group type: OTHER
Intervention: volume controlled ventilation
Description: effects of volume controlled ventilation
Study: NCT04620304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421 SC(dB4C7C22-6 mAb)
Description: The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421 SC(dB4C7C22-6 mAb)
Description: The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421 SC(dB4C7C22-6 mAb)
Description: The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
Study: NCT05520333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIPAS Alcohol
Description: Weekly text messages for three months.
Study: NCT05185934

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food supplement Endocalyx
Description: Patients with COVID-19 infection will be randomized to receive food supplement Endocalyx for 4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with COVID-19 infection will be randomized to receive placebo for 4 months.
Study: NCT05828342

Intervention type: PROCEDURE
Intervention: Endotracheal tube cuff inflation with the loss of resistance syringe method
Description: The cuffs of the endotracheal tubes will be inflated with the epidural loss of resistance syringe, the syringe piston will be released, the syringe piston will be pushed back with oscillation, and then the cuff pressures will be measured and recorded with a cuff manometer (VBM Cuff Pressure Gauge) and an electronic injector that measures cuff pressure (AG Cufill). A three-way vein valve will be used when making this measurement. During the measurement, an epidural resistance loss injector will be attached to one valve, a cuff manometer attached to another valve, and an electronic injector (AG Cufill) measuring cuff pressure to the third track. With this technique, the possibility of leakage due to insertion and removal during measurements will be eliminated.
Study: NCT06208813

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine supplementation
Study: NCT04867759

Intervention type: PROCEDURE
Intervention: Endometrial Biopsy
Description: On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.

Intervention type: PROCEDURE
Intervention: Endometrial Biopsy
Description: On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
Study: NCT02937376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cystein
Description: A trial of exercise before and after 4 weeks of N-acetyl cystein (NAC) supplementation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A trial of exercise before and after 4 weeks of placebo administration.
Study: NCT04868032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology-Motivational Interviewing
Description: Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Education Control
Description: Participants randomized to this condition will be provided with a Fitbit, and will be mailed educational materials about physical activity at 4 time points throughout the intervention period. They will not receive a manual or phone calls with an interventionist.
Study: NCT05424341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: For Gastrocnemius muscle, subject will be in supine position keeping knee fully extended and therapist on affected side in walking position. The subject's ankle joint will be dorsiflexed until a resistance feel and will ask to hold this position and exert 20% of force towards plantar flexion for a period of 5 to 7 seconds. Resistance will be released and relaxation of 5 seconds will be given during which the ankle will was passively dorsiflexed to a new barrier. 5 repetitions will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counterstrain Technique
Description: Therapist places thumb on tender point at plantar fascia insertion while patient in supine position with ipsilateral knee flexed. Plantar flex the toes and ankle while monitoring sore site with thumb, curling around tender point until monitoring thumb feels symptomatic relief. Supination/pronation of foot will be added if necessary. The position of ease will be maintained for 90 secs until tissues beneath monitoring thumb softens. Tender spot is re-evaluated once the foot is returned to neutral without moving the thumb. It will be repeated 3 times for 30 secs resting interval in-between
Study: NCT06313645

Intervention type: OTHER
Intervention: Several biomarkers
Description: Telomere length Mitochondrial DNA copy number (mtDNAcn) MitomiR long non-coding (lnc) RNA TERRA pro-oxidant cytokines \& chemokines
Study: NCT04625283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Participants in the ketamine arm will receive intraoperative and postoperative ketamine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo arm will receive intraoperative and postoperative saline.
Study: NCT04794907

Intervention type: OTHER
Intervention: Observation
Description: Patient data will be collected from eye exams, surveys and medical record review.

Intervention type: OTHER
Intervention: Observation
Description: Patient data will be collected from eye exams, surveys and medical record review.
Study: NCT05706324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
Description: 0.2mL/dose, Inhalation using a nebulizer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
Description: 0.2mL/dose, Inhalation using a nebulizer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
Description: 0.2mL/dose, Inhalation using a nebulizer
Study: NCT05164211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Didgeridoo
Description: the children will have 6 didgeridoo lessons given by a teacher spread over 3 months.
Study: NCT05841511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese handwriting intervention program for children with ASD, named Go Go Handwriting - ASD version
Description: The intervention program was developed and finalized by a group of occupational therapist specialists in the pediatric field. Thirty-six 20-minute activities with twelve activities for each handwriting fundamental skill were designed in this program.~All intervention activities were designed based on the characteristic of Chinese characters and included different types of characters.~The activities designed will also be graded according to the following principle: (1) the similarities between the character given, (2) the complexity of the figure or character in the activities, and (3) the frequency and level of therapist assistance.~Furthermore, a playful and interesting intervention context will also be integratedinto the program with the design of the adventure journey of an astronaut to further facilitate the motivation and participation of the participants in our program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese handwriting intervention program for children with ASD, named Go Go Handwriting - ASD version
Description: The intervention program was developed and finalized by a group of occupational therapist specialists in the pediatric field. Thirty-six 20-minute activities with twelve activities for each handwriting fundamental skill were designed in this program.~All intervention activities were designed based on the characteristic of Chinese characters and included different types of characters.~The activities designed will also be graded according to the following principle: (1) the similarities between the character given, (2) the complexity of the figure or character in the activities, and (3) the frequency and level of therapist assistance.~Furthermore, a playful and interesting intervention context will also be integratedinto the program with the design of the adventure journey of an astronaut to further facilitate the motivation and participation of the participants in our program.
Study: NCT04761003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopy forceps
Description: take pleural biopsy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopy forceps
Description: take pleural biopsy
Study: NCT05751551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized, home-based motor-cognitive training
Description: The simultaneous motor-cognitive training in this study will be conducted in form of exergames (interactive video games) using Senso hardware (DIV-SENSO-H, Dividat GmbH, Schindellegi, Switzerland) - a stepping platform with 5 pressure sensitive plates which is connected to a screen. For the home-based training, a more mobile version of the Dividat Senso will be used: a foldable pressure-sensitive mat. In both devices, stimuli of exergames appear on the screen and the participants have to react by stepping in one of 4 directions (front, back, left, right).~The motor-cognitive training approach allows targeting different cognitive functions such as attention, executive functions, memory, and visuo-spatial functions as well as balance, and strength.~FITT-VP principles will serve as a guideline but based on the functional status of each participant (physical and cognitive), the training sessions will be personalized in terms of training content, intensity and duration.
Study: NCT05115799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy, Physiotherapy, Kinesiology, Scar Massage
Description: The physiotherapist performs passive kinesitherapy on the mastectomized patient with lymphatic thrombus, and scar massage when the arm maintains its greater range of mobility.~The patient will never present pain during the rehabilitation session above 5 in Pain Scale Analog Scale.

Intervention type: OTHER
Group type: OTHER
Intervention: Kinesiotherapy, Physiotherapy, Health Education
Description: These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days